

Richter signed a license and distribution agreement to enhance its fertility portfolio

Budapest, Hungary – 18 September 2018 – Gedeon Richter Plc. (“Richter”) today announced that it has entered into a license and distribution agreement with L.D. Collins & Co. Limited (“L.D. Collins”), a UK based company, to commercialize its 400mg progesterone containing assisted reproduction technology (ART) product, Cyclogest® in 27 EU countries. Marketing authorizations have already been granted in the above territory. Following the transfer of the marketing authorization holder to Richter, the launch of the product is expected to be executed from early 2019.

Under the terms of the agreement Richter shall pay sales related royalties to L.D. Collins subsequent to the launch of the product.

“Cyclogest® is considered a useful addition to our existing fertility portfolio. Being a responsible player of the pharmaceutical universe we are aware of the importance of the productiveness of the female population and we are committed to address women’s needs,” said Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc.

About Cyclogest®

Beside the regulation of ovulation and menstruation, progesterone is essential in establishing and maintaining early pregnancy. Cyclogest® pessaries contain 400mg of progesterone, a naturally occurring progestogen. Cyclogest® prepares the lining of the uterus (endometrium) to be as receptive as possible to the embryo and therefore it is critical to support the luteal phase as part of ART (Assisted Reproductive Technology).

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 4.1 billion (USD 4.9 billion) by the end of 2017, Richter's consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's healthcare field worldwide. Richter is also active in biosimilar product development.

About L.D.Collins

L.D. Collins & Co. Ltd. (www.ldcollins.co.uk), headquartered in the UK, is a niche specialist female healthcare company, and global product owner of a life changing IVF medication, Cyclogest. Founded in 1970 by Laurence Collins, L.D. Collins now has commercial presence in over 58 countries worldwide, including many markets such as the UK where Cyclogest is the drug of choice. L.D. Collins recently invested into a multimillion dollar clinical trial across Europe to gain the IVF indication for Cyclogest. L.D. Collins's strategic direction is focused on expanding their global footprint and developing their portfolio of female health products through research and acquisition.

For more information:

Investors:

Katalin Ördög: +36 1 431 5680

Media:

Zsuzsa Beke: +36 1 431 4888